Probing the structure and function of the intracellular domain of cys-loop receptors

探讨cys环受体胞内结构域的结构和功能

• 批准号: 10201368
• 负责人: Michaela Jansen
• 金额: $ 38.17万
• 依托单位: TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-01 至 2021-12-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10201368
• 关键词: Address; Alzheimer' s Disease; Amino Acid Substitution; Amino Acids; Anesthetics; Anti-Anxiety Agents; Antiemetics; Antiepileptic Agents; Anxiety; Anxiety Disorders; Architecture; Atherosclerosis; Binding; Biochemical; Biological Assay; Cations; Cause of Death; Cell membrane; Characteristics; Chimera organism; Choline; Cholinergic Receptors; Clinical; Complex; Coupled; Covalent Interaction; Cryoelectron Microscopy; Dementia; Diabetes Mellitus; Disease; Drug Targeting; Dyes; Electrophysiology (science); Environment; Epilepsy; Eukaryota; Extracellular Domain; Family; Family member; Foundations; Funding; Glycine; Heart Diseases; Homo; Human; Inflammatory; Inflammatory Bowel Diseases; Investigation; Ion Channel; Ion Channel Gating; Knowledge; Length; Ligands; Link; Mass Spectrum Analysis; Mediating; Membrane Transport Proteins; Mental Depression; Methods; Modification; Molecular; Molecular Chaperones; Molecular Conformation; Muscle relaxants; Myasthenia Gravis; Nerve Degeneration; Neurologic; Neurotransmitter Receptor; Nicotine Dependence; Pain; Parkinson Disease; Pharmaceutical Preparations; Pharmacology; Pharmacotherapy; Plant Resins; Proteins; Publishing; Resistance; Role; Schizophrenia; Sepsis; Serotonin; Shapes; Sodium Chloride; Solvents; Structure; Testing; Transmembrane Domain; base; burden of illness; clinical effect; design; disability; esterase; experimental study; gamma-Aminobutyric Acid; inhibitor/antagonist; innovation; insight; maltose-binding protein; nervous system disorder; neuropsychiatric disorder; neuropsychiatry; novel; overexpression; prevent; protein complex; protein protein interaction; receptor; smoking cessation; targeted treatment; therapeutic development

Project Summary Pentameric ligand-gated ion channels (pLGICs), also called Cys-loop receptors in eukaryotes, include the receptors for acetylcholine, serotonin, GABA and glycine. They are involved in numerous neuropsychiatric, neurologic, and inflammatory diseases. All Cys-loop receptor family members in metazoans contain three structural domains: an extracellular domain (ECD), a transmembrane domain (TMD), and an intracellular domain (ICD). The ECD and TMD are architecturally conserved between receptor families. The ICD is poorly conserved in both length and amino-acid composition and, for many subunits, contains large regions of predicted structural disorder. Due to the challenge of working with the ICDs of pentameric receptors, they have been essentially overlooked in terms of rigorous mechanistic characterization and direct exploration as pharmacological targets. The ICD is involved in finetuning plasma membrane expression levels, targeting, and function, in part mediated by protein-protein interactions (PPI) for example with chaperones. We envision that mechanistic knowledge of chaperone-mediated modulation will uncover new PPI drug targets. Through our published studies of the ICD we defined a linker that allowed for structure determination of the first in class structures of homo- and heteropentameric GABAA receptors. We also established that the ICD alone assembles into pentamers, establishing a novel role for the ICD in oligomeric assembly. In this competitive renewal we propose a multi- layered approach leveraging both soluble ICD chimeras and full-length receptors together with results obtained during the previous funding period in careful consideration of recently-published pLGIC structures. We discovered that the resistance to inhibitors of choline esterase (Ric-3) chaperone binds to a 24-amino acid L1- MX segment of 5-HT3A subunits. With the new proposed specific aims (SA) we will: (SA1) determine the role of the L1-MX segment in RIC-3 modulation of pLGIC assembly, (SA2) identify the segments within nAChR ICDs that mediate novel nAChR regulator (NACHO) modulation of pentameric assembly, and (SA3) characterize the mechanism by which opening of cation-conducting pLGICs involves translocation of the L1-MX segment through the MA-helix framed portals. In each aim, we will use biochemical and electrophysiological methods, coupled with overexpressed and purified proteins or proteins in their cellular environment. We anticipate that our studies will provide the basis for a novel class of targets for therapeutic development, PPI modulators for pentameric channel intracellular domains.

项目摘要 五聚体配体门控离子通道(PLGICs)，在真核生物中也被称为Cys环受体，包括 乙酰胆碱、5-羟色胺、GABA和甘氨酸的受体。他们参与了许多神经精神病学的研究， 神经学和炎症性疾病。后生动物中的所有Cys-loop受体家族成员都包含三个 结构域：胞外区(ECD)、跨膜区(TMD)和胞内区 (ICD)。ECD和TMD在受体家族之间结构上是保守的。ICD保存得很差 在长度和氨基酸组成上都是如此，对于许多亚基来说，它包含预测的结构的大区域 无序。由于研究五聚体受体ICD的挑战，它们基本上是 忽视了作为药理靶标的严格的机械性表征和直接探索。 ICD参与微调质膜表达水平、靶向性和功能，部分地介导 通过蛋白质-蛋白质相互作用(PPI)，例如与伴侣。我们设想机械论的知识 伴侣介导的调节将发现新的PPI药物靶点。通过我们发表的关于ICD的研究 我们定义了一个链接器，它允许确定HOMO-AND类结构中的第一个结构 异五聚体GABAA受体。我们还证实，ICD单独组装成五聚体， 确立了ICD在低聚物组装中的新角色。在这场竞争性续签中，我们提出了多项- 利用可溶性ICD嵌合体和全长受体的分层方法及其结果 在上一个供资期间，仔细考虑了最近公布的pLGIC结构。我们 发现对胆碱酯酶(Ric-3)抑制剂的抗性与24个氨基酸的L1-L1结合。 5-HT3A亚基的MX片段。有了新提出的具体目标(SA)，我们将：(SA1)确定 PLGIC组件RIC-3调制中的L1-MX片段(SA2)识别nAChR ICD内 介导新型nAChR调节剂(Nacho)对五聚体组装的调制，并(SA3)表征 阳离子传导pLGICs开放涉及L1-MX片段移位的机制 MA-螺旋构成了入口。在每个目标中，我们将使用生化和电生理方法，结合 在其细胞环境中过度表达和纯化的蛋白质或蛋白质。我们预计我们的 研究将为治疗开发的一类新靶点提供基础，PPI调节剂可用于 五聚体通道胞内结构域。